Valuation : Capricor Therapeutics, Inc.

Market Cap 55Cr 47Cr 44Cr 40Cr 76Cr 5.16TCr 76Cr 522.84Cr 202.89Cr 2.65TCr 205.22Cr 200.74Cr 8.53TCr P/E 2026 *
-4.13x
P/E 2027 * -6.31x
Enterprise Value 55Cr 47Cr 44Cr 40Cr 76Cr 5.16TCr 76Cr 522.84Cr 202.89Cr 2.65TCr 205.22Cr 200.74Cr 8.53TCr EV / Sales 2026 *
33.2x
EV / Sales 2027 * 9.67x
Free-Float
90.56%
Yield 2026 *
-
Yield 2027 * -
1 day+1.29%
1 week-1.98%
Current month-5.15%
1 month+125.42%
3 months-66.37%
6 months-63.14%
Current year-67.43%
1 week 9.06
Extreme 9.065
11
1 month 3.73
Extreme 3.73
11
Current year 2.96
Extreme 2.96
36.82
1 year 2.96
Extreme 2.96
40.37
3 years 2.68
Extreme 2.68
40.37
5 years 2.56
Extreme 2.56
40.37
10 years 0.88
Extreme 0.88
42.5
Manager TitleAgeSince
Chief Executive Officer 62 20/11/2013
Director of Finance/CFO 40 01/01/2018
Chief Tech/Sci/R&D Officer - 13/05/2025
Director TitleAgeSince
Chairman 70 01/11/2013
Director/Board Member 68 20/11/2013
Director/Board Member 79 20/11/2013
Date Insider Type Main position Quantity % Market Cap. Importance
26/05/26 Free

CHIEF COMMERCIAL OFFICER

80,000 0.1383%
18/05/26 Exercice

Chief Financial Officer

6,000 0.0104%
13/05/26 Exercice

Chairman

7,874 0.0136%
Change 5-day change 1-year change 3-year change Capi.($)
+1.29%-1.98%+58.25%+42.21% 55Cr
-1.79%-2.27%+50.90%+89.03% 6.8TCr
-2.06%-0.18%+41.53%+88.17% 6.49TCr
-0.31%+6.54%-11.39%+457.82% 2.76TCr
-3.00%-2.90%+39.40%+9.41% 2.57TCr
+0.86%+1.65%+0.25%-14.78% 2.61TCr
-1.46%+0.42%+24.07%-18.70% 2.01TCr
-2.96%-15.21%+210.71%+370.84% 1.72TCr
-1.49%-4.88%-0.41%+530.26% 1.49TCr
-0.20%+8.37%+57.87%+159.50% 1.46TCr
Average -1.11%+0.03%+47.12%+171.38% 2.8TCr
Weighted average by Cap. -1.51%+0.17%+42.32%+144.88%

Financials

2026 *2027 *
Net sales 1.64Cr 1.42Cr 1.33Cr 1.22Cr 2.28Cr 155.31Cr 2.28Cr 16Cr 6.11Cr 80Cr 6.18Cr 6.04Cr 256.71Cr 5.65Cr 4.87Cr 4.58Cr 4.18Cr 7.82Cr 533.81Cr 7.84Cr 54Cr 21Cr 273.88Cr 21Cr 21Cr 882.32Cr
Net income -13Cr -11Cr -11Cr -9.76Cr -18Cr -1.25TCr -18Cr -126.27Cr -49Cr -639.37Cr -50Cr -48Cr -2.06TCr -8.95Cr -7.7Cr -7.25Cr -6.62Cr -12Cr -845.11Cr -12Cr -86Cr -33Cr -433.6Cr -34Cr -33Cr -1.4TCr
Net Debt - -
Logo Capricor Therapeutics, Inc.
Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program focuses on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate, Deramiocel (also referred to as CAP-1002), is an allogeneic cardiac-derived cell therapy. The clinical development program for Deramiocel has focused primarily on adolescents and young adults with DMD, including many patients who are non-ambulatory and experiencing progressive cardiac and skeletal muscle decline. Its StealthX exosome platform program consists of engineered exosomes for vaccine and therapeutic development. The StealthX vaccine is a proprietary vaccine developed internally utilizing exosomes that were engineered to express either spike or nucleocapsid proteins on the surface.
Employees
231
Date Price Change Volume
04/26/04 $9.400 +1.29% 25,55,651
03/26/03 $9.280 -6.17% 40,64,904
02/26/02 $9.890 -1.20% 51,65,484
01/26/01 $10.01 +1.01% 63,08,555
31/26/31 $9.910 +3.34% 45,58,777
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
9.400USD
Average target price
28.50USD
Spread / Average Target
+203.19%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CAPR Stock